Akcea Therapeutics Inc
AKCA
AKCA was delisted on the 9th of October, 2020.
58 hedge funds and large institutions have $337M invested in Akcea Therapeutics Inc in 2017 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 19 increasing their positions, 14 reducing their positions, and 6 closing their positions.
217% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 6
36% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 14
29% more funds holding
Funds holding: 45 → 58 (+13)
30% less capital invested
Capital invested by funds: $480M → $337M (-$143M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$24.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$23.8M |
| 3 |
BlackRock
New York
|
+$19.4M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.06M |
| 5 |
IHM
Iguana Healthcare Management
New York
|
+$1.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$26.4M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$8.43M |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$4.26M |
| 4 |
ACM
Atika Capital Management
New York
|
-$2.49M |
| 5 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$2.23M |
AKCA Hedge Fund Activity: Q4 2017 in Review
58 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Akcea Therapeutics Inc (AKCA) for Q4 2017, worth a combined $337M — down 30% from $480M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new AKCA positions and 6 closed out — a net gain of 13 holders — while 19 added to existing stakes and 14 trimmed.
The largest buyer was BB Biotech, opening a new position worth an estimated $24.5M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $26.4M sold.
- 58 institutional investors held Akcea Therapeutics Inc (AKCA) as of Q4 2017, up from 45 in Q3 2017.
- Funds reported $337M of Akcea Therapeutics Inc stock for Q4 2017, down 30% quarter-over-quarter.
- 19 funds opened new Akcea Therapeutics Inc positions in Q4 2017 and 6 closed out, a net change of +13 holders.
- The largest Akcea Therapeutics Inc buyer in Q4 2017 was BB Biotech, an estimated $24.5M added.
- The largest Akcea Therapeutics Inc seller in Q4 2017 was T. Rowe Price Associates, an estimated $26.4M sold.
Based on aggregated 13F filings for Q4 2017.